Klivira
Request demo

Navigating Aetna Aimovig Prior Authorization for Migraine Therapy

Successfully managing Aetna Aimovig prior authorization is critical for ensuring timely access to this CGRP receptor antagonist for your patients. Klivira provides the operational insights needed to navigate Aetna's specific requirements.

For revenue cycle directors and prior authorization coordinators, understanding payer-specific nuances is paramount. This guide outlines the key considerations for submitting and managing Aetna Aimovig (erenumab) prior authorization requests, helping to reduce administrative burden and improve approval rates for preventive migraine therapy.

Aimovig (Erenumab): Clinical Context and Aetna Coverage

Aimovig (erenumab) is a CGRP receptor antagonist indicated for the preventive treatment of chronic and episodic migraine. As a specialty medication, it typically requires prior authorization from Aetna. Coverage criteria often include documentation of diagnosis, prior therapeutic trials of other preventive medications (step therapy), and patient-specific clinical factors.

Aetna Prior Authorization Submission Channels for Specialty Medications

Aetna's submission channels for specialty drugs like Aimovig vary based on benefit category. Medical-benefit requests, common for certain injectable specialty medications, are primarily routed through the Availity provider portal or via X12 278 transactions. For pharmacy-benefit requests, submissions are handled by CVS Caremark, Aetna's PBM, often through ePA partners like CoverMyMeds or Surescripts for retail, or CVS Caremark's direct portal for mail-order. It is crucial to verify the correct benefit and channel for each Aimovig prescription.

Accessing Aetna's Medical Necessity Criteria: Clinical Policy Bulletins (CPBs)

Aetna publishes its medical necessity criteria for medications, including specialty drugs like Aimovig, in its public Clinical Policy Bulletins (CPBs). These CPBs are versioned and dated, serving as the canonical source for coverage requirements. The relevant CPB will detail the specific clinical indications, step therapy requirements (e.g., trials of generic preventives), and documentation needed for Aimovig approval.

Understanding Aetna's Turnaround Times for Aimovig PA

Aetna's prior authorization turnaround times are influenced by state-specific regulations and NCQA Utilization Management accreditation standards. For Medicare Advantage plans, Aetna is also an impacted payer under CMS-0057-F, mandating 72-hour standard and 24-hour expedited decisions on a phased timeline. While commercial lines are not directly impacted by CMS-0057-F, understanding these varying timeframes is essential for managing patient expectations and care coordination.

Common Denial Reasons and Aetna's Appeal Process for Aimovig

Denials for Aimovig prior authorization commonly stem from medical necessity issues, insufficient clinical documentation, or failure to meet step therapy requirements. Aetna returns denial reasons via X12 835/277 transactions or portal status updates, using standard CARC and RARC vocabularies. The appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeals, with expedited options available for urgent situations. Timely filing windows and external review eligibility follow state and federal guidelines.

Frequently asked questions

How do I submit an Aetna Aimovig prior authorization request?

Aetna's submission process for Aimovig (erenumab) depends on whether it falls under the medical or pharmacy benefit. Medical benefit requests are typically submitted via the Availity portal or X12 278. Pharmacy benefit requests are managed by CVS Caremark and can be submitted through ePA partners like CoverMyMeds or Surescripts, or CVS Caremark's direct provider portal for mail-order. Always verify the specific benefit and channel for the patient's plan.

What Aetna policies govern Aimovig coverage?

Aimovig coverage is governed by Aetna's Clinical Policy Bulletins (CPBs). These publicly available documents outline the specific medical necessity criteria, including indications, dosage, and any required step therapy protocols. Reviewing the most current, versioned CPB for Aimovig (erenumab) is essential to understand Aetna's requirements.

What are common reasons for Aetna to deny Aimovig prior authorization?

Common reasons for Aetna to deny Aimovig (erenumab) prior authorization include a lack of documented medical necessity, insufficient clinical information to support the diagnosis or treatment plan, or failure to meet step therapy requirements (e.g., trials of generic preventive migraine therapies). Off-label use without compendium support can also lead to denials.

Does Aetna require step therapy for Aimovig?

Yes, step therapy is a common requirement for specialty medications like Aimovig (erenumab), especially for preventive migraine therapies. Aetna's specific step therapy protocols, which often involve trials of generic preventive medications, are detailed within the applicable Clinical Policy Bulletin (CPB) for Aimovig.

What is the typical Aetna PA turnaround time for Aimovig?

Aetna's prior authorization turnaround times for Aimovig (erenumab) vary. For commercial plans, timeframes are often governed by state insurance regulations and NCQA standards. For Medicare Advantage, Medicaid managed-care, and QHP-on-FFM lines, CMS-0057-F mandates 72-hour standard and 24-hour expedited decisions. Always consult the specific plan's requirements and state mandates.

Related coverage

Other aimovig prior authorization by payer

Other aimovig prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo